Last reviewed · How we verify
WX-UK1 in combination with Capecitabine — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
WX-UK1 in combination with Capecitabine (WX-UK1 in combination with Capecitabine) — Heidelberg Pharma AG.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| WX-UK1 in combination with Capecitabine TARGET | WX-UK1 in combination with Capecitabine | Heidelberg Pharma AG | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- WX-UK1 in combination with Capecitabine CI watch — RSS
- WX-UK1 in combination with Capecitabine CI watch — Atom
- WX-UK1 in combination with Capecitabine CI watch — JSON
- WX-UK1 in combination with Capecitabine alone — RSS
Cite this brief
Drug Landscape (2026). WX-UK1 in combination with Capecitabine — Competitive Intelligence Brief. https://druglandscape.com/ci/wx-uk1-in-combination-with-capecitabine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab